These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 18337603)

  • 1. VEGF inhibition and renal thrombotic microangiopathy.
    Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
    N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF inhibition and renal thrombotic microangiopathy.
    Nochy D; Lefaucheur C; Hill G
    N Engl J Med; 2008 Jul; 359(2):206; author reply 206-7. PubMed ID: 18618951
    [No Abstract]   [Full Text] [Related]  

  • 3. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
    Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
    Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 6. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
    Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
    Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.
    Roncone D; Satoskar A; Nadasdy T; Monk JP; Rovin BH
    Nat Clin Pract Nephrol; 2007 May; 3(5):287-93. PubMed ID: 17457362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.
    Suga S; Kim YG; Joly A; Puchacz E; Kang DH; Jefferson JA; Abraham JA; Hughes J; Johnson RJ; Schreiner GF
    Kidney Int; 2001 Oct; 60(4):1297-308. PubMed ID: 11576344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
    Eremina V; Quaggin SE
    Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab-associated glomerular microangiopathy.
    Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
    Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
    Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
    BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF inhibition and renal thrombotic microangiopathy.
    Katavetin P; Katavetin P
    N Engl J Med; 2008 Jul; 359(2):205-6; author reply 206-7. PubMed ID: 18614790
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal involvement in preeclampsia: similarities to VEGF ablation therapy.
    Müller-Deile J; Schiffer M
    J Pregnancy; 2011; 2011():176973. PubMed ID: 21494322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
    Zhang PL; Raza S; Li W; Kanaan HD
    Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
    Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
    Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.
    Yahata M; Nakaya I; Sakuma T; Sato H; Aoki S; Soma J
    BMC Res Notes; 2013 Nov; 6():450. PubMed ID: 24207130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.
    Nagayama Y; Yamano M; Yagame M; Nariyama T; Takahashi M; Kawamoto M; Matsui K
    BMC Nephrol; 2019 Oct; 20(1):375. PubMed ID: 31623576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
    Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
    Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
    Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
    Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vegfa protects the glomerular microvasculature in diabetes.
    Sivaskandarajah GA; Jeansson M; Maezawa Y; Eremina V; Baelde HJ; Quaggin SE
    Diabetes; 2012 Nov; 61(11):2958-66. PubMed ID: 23093658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.